Whanin Pharm Co (XKRX:016580) Debt-to-Equity : 0.00 (As of Mar. 2024)

View and export this data going back to 1996. Start your Free Trial

What is Whanin Pharm Co Debt-to-Equity?

Whanin Pharm Co's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was ₩335 Mil. Whanin Pharm Co's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was ₩281 Mil. Whanin Pharm Co's Total Stockholders Equity for the quarter that ended in Mar. 2024 was ₩362,483 Mil. Whanin Pharm Co's debt to equity for the quarter that ended in Mar. 2024 was 0.00.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Whanin Pharm Co's Debt-to-Equity or its related term are showing as below:

During the past 13 years, the highest Debt-to-Equity Ratio of Whanin Pharm Co was 0.01. The lowest was 0.00. And the median was 0.01.

XKRX:016580's Debt-to-Equity is not ranked ^*
in the Drug Manufacturers industry.
Industry Median: 0.3
* Ranked among companies with meaningful Debt-to-Equity only.

Whanin Pharm Co Debt-to-Equity Historical Data

The historical data trend for Whanin Pharm Co's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Whanin Pharm Co Debt-to-Equity Chart

Whanin Pharm Co Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

Get a 7-Day Free Trial

0.01

Whanin Pharm Co Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Debt-to-Equity	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Whanin Pharm Co's Debt-to-Equity

For the Drug Manufacturers - Specialty & Generic subindustry, Whanin Pharm Co's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Whanin Pharm Co's Debt-to-Equity Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Whanin Pharm Co's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Whanin Pharm Co's Debt-to-Equity falls into.

Whanin Pharm Co Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Whanin Pharm Co's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(324.969	+	307.056)	/	358207.481
	=	0.00

Whanin Pharm Co's Debt to Equity Ratio for the quarter that ended in Mar. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(334.718	+	280.661)	/	362483.111
	=	0.00

Whanin Pharm Co (XKRX:016580) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Whanin Pharm Co Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Whanin Pharm Co's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Whanin Pharm Co (XKRX:016580) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Whanin Pharm Co Ltd (XKRX:016580) » Definitions » Debt-to-Equity

Traded in Other Exchanges

N/A

Address

84-1 Munjeong-dong, Songpa-gu, Seoul, KOR, 138-200

Website

http://www.whanin.co.kr

Whanin Pharm Co Ltd is a pharmaceutical company. The company develops, manufactures, markets, and sells the therapeutic products. It offers antibiotics, cardiovascular drugs, CNS stimulants, gastrointestinal drugs, multivitamins and other products. The company's products include Antiasthmatics; Antidepressants; Antipsychotics; Anxiolytics and hypnotics; and Antiepileptics.

Whanin Pharm Co (XKRX:016580) Headlines

No Headlines